Eli Lilly and Company $LLY Holdings Trimmed by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 417,655 shares of the company’s stock after selling 11,495 shares during the period. Eli Lilly and Company makes up 1.3% of Eurizon Capital SGR S.p.A.’s holdings, making the stock its 15th biggest position. Eurizon Capital SGR S.p.A.’s holdings in Eli Lilly and Company were worth $485,579,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Torren Management LLC grew its stake in shares of Eli Lilly and Company by 357.1% in the third quarter. Torren Management LLC now owns 32 shares of the company’s stock valued at $37,000 after acquiring an additional 25 shares in the last quarter. Marshall & Sterling Wealth Advisors Inc. increased its position in Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after acquiring an additional 15 shares during the period. Foresight Capital Management Advisors Inc. acquired a new stake in Eli Lilly and Company in the 3rd quarter worth about $49,000. AlphaCentric Advisors LLC acquired a new stake in Eli Lilly and Company in the 1st quarter worth about $42,000. Finally, Caitlin John LLC bought a new stake in Eli Lilly and Company in the 2nd quarter valued at about $64,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.3%

LLY stock opened at $1,433.34 on Friday. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,460.00. The business has a 50-day simple moving average of $1,236.58 and a 200 day simple moving average of $1,108.27. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The company has a market cap of $1.35 trillion, a PE ratio of 46.52, a price-to-earnings-growth ratio of 1.72 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same period in the prior year, the company posted $7.02 earnings per share. Sell-side analysts anticipate that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is 22.46%.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Jefferies Financial Group increased their target price on shares of Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the stock a “buy” rating in a research report on Monday. Weiss Ratings downgraded shares of Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday, October 30th. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Citigroup boosted their price target on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Finally, Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,416.64.

More Eli Lilly and Company News

These are some of the LLY news items that stood out recently:

• Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania facility to make injectable medicines, including next-generation candidate retatrutide. The investment could expand manufacturing capacity for future demand and is expected to create 850 permanent jobs, though the benefits will take time to materialize. Lilly facility announcement
• Positive Sentiment: A Phase 3b study found that combining Zepbound with Taltz improved and sustained outcomes in adults with psoriatic arthritis and obesity compared with Taltz alone. The results could support broader use of Lilly’s medicines in patients with both conditions. Phase 3b study announcement
• Neutral Sentiment: Lilly’s obesity collaboration with Fauna Bio designated a second discovery target using AI-based research. It adds to the early-stage pipeline, but any commercial impact is uncertain and likely years away. Fauna Bio announcement

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.